Physician profile
Christopher Scully
NPI 1760437842
$2,783.92
in general payments reported to CMS, 2019-2025
24 companies · $188 in 2025
The $188 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $710 · 2020: $418 · 2021: $554 · 2022: $397 · 2023: $355 · 2024: $161 · 2025: $188.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $705.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $704.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $452.75 | 2019-2022 | |
| Amgen INC. | $332.19 | 2019-2023 | Enbrel, Tavneos, Otezla |
| Novartis Pharmaceuticals Corporation | $330.42 | 2019-2025 | |
| Abbvie INC. | $235.96 | 2019-2023 | Rinvoq |
| E.R. Squibb & Sons, L.L.C. | $223.54 | 2019-2025 | Orencia |
| Glaxosmithkline, LLC. | $172.92 | 2019-2024 | Benlysta |
| Ucb, INC. | $139.03 | 2019-2024 | Bimzelx |
| Horizon Therapeutics Plc | $138.60 | 2019-2023 | Krystexxa |
| Organon LLC | $119.15 | 2021-2025 | Hadlima, Renflexis |
| Genentech USA, INC. | $111.94 | 2019-2025 | Gazyva |
| Alexion Pharmaceuticals, INC. | $82.38 | 2019-2022 | |
| Pfizer INC. | $71.07 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $65.73 | 2021-2025 | Saphnelo |
| Mallinckrodt Enterprises LLC | $46.28 | 2019 | |
| Celgene Corporation | $35.29 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $35.15 | 2019-2021 | |
| Vertex Pharmaceuticals Incorporated | $32.90 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.39 | 2019-2021 | |
| Genzyme Corporation | $31.53 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $22.64 | 2019 | |
| Kiniksa Pharmaceuticals, Ltd. | $19.78 | 2022 | |
| Aurinia Pharma U.S., INC. | $19.17 | 2023 | Lupkynis |
| Ultragenyx Pharmaceutical INC. | $16.83 | 2021 | |
| Ani Pharmaceuticals, INC. | $16.28 | 2025 | Purified Cortrophin Gel |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Scully listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.